Dean A Lee

List of Publications by Year
in descending order

192	10,223	36303	40979
papers	citations	51 h-index	93 g-index

202	202	202	11795
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands. Immunity, 2004, 20, 107-118.	14.3	517
2	Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PLoS ONE, 2012, 7, e30264.	2.5	488
3	A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 2012, 119, 5697-5705.	1.4	437
4	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation, 2016, 126, 3363-3376.	8.2	399
5	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	7.2	363
6	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Research, 2015, 75, 3505-3518.	0.9	327
7	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7788-E7797.	7.1	320
8	Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy. Stem Cells Translational Medicine, 2013, 2, 274-283.	3.3	293
9	Phase 1 clinical trial using mbIL21 ex vivoâ€“expanded donor-derived NK cells after haploidentical transplantation. Blood, 2017, 130, 1857-1868.	1.4	256
10	Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood, 2013, 122, 1341-1349.	1.4	243
11	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigenâ€“Matched Unrelated and Related Donors. Biology of Blood and Marrow Transplantation, 2014, 20, 1975-1981.	2.0	207
12	T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Molecular Therapy, 2013, 21, 629-637.	8.2	200
13	Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Research, 2011, 71, 3516-3527.	0.9	171
14	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10660-10665.	7.1	171
15	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology, 2017, 177, 457-466.	2.5	158
16	Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS ONE, 2013, 8, e76781.	2.5	155
17	Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children. Neurosurgery, 2011, 68, 588-600.	1.1	143
18	Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous Î³Î´ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor. Molecular Therapy, 2013, 21, 638-647.	8.2	134

#	Article	IF	Citations
19	piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. Human Gene Therapy, 2010, 21, 427-437.	2.7	124
20	Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies. Clinical Cancer Research, 2014, 20, 5708-5719.	7.0	114
21	Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 1290-1298.	2.0	113
22	Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells. Journal of Visualized Experiments, 2011, , .	0.3	109
23	Aggressive natural killer-cell leukemiaÂmutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nature Communications, 2018, 9, 1567.	12.8	107
24	Engineering lymph node homing of ex vivoâ€“expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood, 2012, 119, 5164-5172.	1.4	106
25	Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials. PLoS ONE, 2013, 8, e57838.	2.5	104
26	Growth and Activation of Natural Killer CellsEx Vivofrom Children with Neuroblastoma for Adoptive Cell Therapy. Clinical Cancer Research, 2013, 19, 2132-2143.	7.0	101
27	Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. , 2017, 5, 98.		101
28	Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. Human Gene Therapy, 2012, 23, 444-450.	2.7	99
29	Evaluation of In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msup><mml:mrow><mml:mtext>CD</mml:mtext><mml:mn mathvariant="bold">33</mml:mn></mml:mrow><mml:mrow><mml:mo mathvariant="bold">+</mml:mo></mml:mrow></mml:msup></mml:math>Acute Myeloid Leukemia. Advances in Hematology, 2012, 2012, 1-10.	1.0	94
30	Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS ONE, 2018, 13, e0191358.	2.5	93
31	The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Therapy, 2011, 18, 849-856.	4.5	91
32	Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells. Stem Cells, 2017, 35, 1065-1079.	3.2	89
33	The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. Pharmaceutical Research, 2015, 32, 779-792.	3.5	86
34	Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nature Communications, 2016, 7, 11154.	12.8	86
35	Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood, 2014, 124, 3241-3249.	1.4	85
36	IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-Î³ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. Molecular Immunology, 2017, 88, 138-147.	2.2	84

#	Article	IF	Citations
37	Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Frontiers in Immunology, 2019, 10, 2873.	4.8	84
38	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	2.0	83
39	Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunological Reviews, 2019, 290, 85-99.	6.0	81
40	Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. OncoImmunology, 2016, 5, e1115178.	4.6	79
41	CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood, 2020, 136, 2416-2427.	1.4	77
42	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer, 2016, 122, 3316-3326.	4.1	75
43	Sleeping Beauty System to Redirect T-cell Specificity for Human Applications. Journal of Immunotherapy, 2013, 36, 112-123.	2.4	74
44	A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry. PLoS ONE, 2015, 10, e0141074.	2.5	71
45	Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. Cytotherapy, 2016, 18, 653-663.	0.7	68
46	IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors. Journal of Immunology, 2010, 184, 2348-2354.	0.8	67
47	NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer Journal, 2021, 11, 146.	6.2	67
48	Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Scientific Reports, 2019, 9, 14916.	3.3	66
49	Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood, 2014, 124, 403-411.	1.4	63
50	The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3. Scientific Reports, 2017, 7, 45266.	3.3	61
51	Autologous Bone Marrow Mononuclear Cells Reduce Therapeutic Intensity for Severe Traumatic Brain Injury in Children*. Pediatric Critical Care Medicine, 2015, 16, 245-255.	0.5	60
52	Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Research, 2017, 19, 76.	5.0	59
53	Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. Journal of Allergy and Clinical Immunology, 2019, 143, 346-358.e6.	2.9	59
54	Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integrative Biology (United Kingdom), 2013, 5, 231-238.	1.3	58

#	Article	IF	Citations
55	Adoptive T-cell therapy improves treatment of canine nonâ€“Hodgkin lymphoma post chemotherapy. Scientific Reports, 2012, 2, 249.	3.3	57
56	Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. Journal of Visualized Experiments, 2018, , .	0.3	53
57	Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Molecular Immunology, 2013, 54, 296-301.	2.2	50
58	The role of AhR in transcriptional regulation of immune cell development and function. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188335.	7.4	49
59	Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro-Oncology, 2020, 22, 1214-1225.	1.2	48
60	Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNÎ³ secretion. OncoImmunology, 2016, 5, e1100790.	4.6	46
61	Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia, 2022, 36, 155-164.	7.2	43
62	Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells. Journal of Immunotherapy, 2013, 36, 319-329.	2.4	42
63	Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. Frontiers in Immunology, 2017, 8, 391.	4.8	42
64	Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro-Oncology, 2020, 22, 1302-1314.	1.2	42
65	Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clinical and Experimental Immunology, 2013, 172, 104-112.	2.6	41
66	Liver transplantation for severe hepatic graft-versus-host disease: An analysis of aggregate survival data. Liver Transplantation, 2005, 11, 525-531.	2.4	40
67	Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies. Cancer Research, 2010, 70, 3915-3924.	0.9	40
68	Natural killer cell adoptive immunotherapy: Coming of age. Clinical Immunology, 2017, 177, 3-11.	3.2	40
69	NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells. Frontiers in Immunology, 2016, 7, 521.	4.8	39
70	The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation. Oncogene, 2013, 32, 1691-1701.	5.9	38
71	TGFÎ² Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers, 2018, 10, 423.	3.7	38
72	Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer Immunology Research, 2018, 6, 1174-1185.	3.4	38

#	Article	IF	Citations
73	Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunology, Immunotherapy, 2018, 67, 575-587.	4.2	36
74	Natural killer cell therapy and aerosol interleukinâ€2 for the treatment of osteosarcoma lung metastasis. Pediatric Blood and Cancer, 2014, 61, 618-626.	1.5	35
75	Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. Stem Cells, 2019, 37, 1481-1491.	3.2	35
76	Natural killer cells in malignant hematology: A primer for the non-immunologist. Blood Reviews, 2017, 31, 1-10.	5.7	34
77	Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Research and Therapy, 2021, 12, 211.	5.5	33
78	A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomedical Microdevices, 2010, 12, 855-863.	2.8	30
79	Haploidentical Hematopoietic Stem Cell Transplantation asÂaÂPlatform for Post-Transplantation Cellular Therapy. Biology of Blood and Marrow Transplantation, 2015, 21, 1714-1720.	2.0	30
80	Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia, 2017, 31, 234-237.	7.2	30
81	Aerosol interleukinâ€2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatric Blood and Cancer, 2014, 61, 1362-1368.	1.5	29
82	Tumor Lysing Genetically Engineered T Cells Loaded with Multi-Modal Imaging Agents. Scientific Reports, 2014, 4, 4502.	3.3	29
83	Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. Journal of Immunotherapy, 2016, 39, 205-217.	2.4	29
84	Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells. Journal of Immunotherapy, 2018, 41, 64-72.	2.4	29
85	Natural Killer Cells for Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 341-353.	1.6	28
86	Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21. Methods in Molecular Biology, 2016, 1441, 175-193.	0.9	27
87	Combined Stimulation with Interleukin-18 and Interleukin-12 Potently Induces Interleukin-8 Production by Natural Killer Cells. Journal of Innate Immunity, 2017, 9, 511-525.	3.8	27
88	Universal Artificial Antigen Presenting Cells to Selectively Propagate T Cells Expressing Chimeric Antigen Receptor Independent of Specificity. Journal of Immunotherapy, 2014, 37, 204-213.	2.4	26
89	Immunotherapeutic Challenges for Pediatric Cancers. Molecular Therapy - Oncolytics, 2019, 15, 38-48.	4.4	26
90	Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. Journal of Neuro-Oncology, 2019, 142, 395-407.	2.9	25

#	Article	IF	Citations
91	HIV false positivity after hepatitis B vaccination. Lancet, The, 1992, 339, 1060.	13.7	24
92	Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation. Frontiers in Immunology, 2018, 9, 1711.	4.8	24
93	NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy, 2012, 4, 305-313.	2.0	23
94	Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of â€œsenescentâ€•NK cells to lose CD57 expression and start expressing NKG2A. PLoS ONE, 2018, 13, e0208469.	2.5	23
95	Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Molecular Imaging and Biology, 2016, 18, 838-848.	2.6	22
96	Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells. Scientific Reports, 2017, 7, 12083.	3.3	22
97	Adoptive immunotherapy with doubleâ€bright (CD56^{bright}/CD16^{bright}) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proofâ€ofâ€concept study. British Journal of Haematology, 2021, 195, 710-721.	2.5	22
98	Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Frontiers in Immunology, 2020, 11, 2196.	4.8	21
99	Mentoring in Pediatric Oncology. Journal of Pediatric Hematology/Oncology, 2013, 35, 456-461.	0.6	20
100	Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. Journal of Neuro-Oncology, 2015, 125, 133-141.	2.9	20
101	Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews, 2019, 38, 573-594.	5.9	20
102	NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells. Blood, 2018, 132, 590-590.	1.4	20
103	Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Journal of Molecular Medicine, 2013, 91, 459-472.	3.9	19
104	Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Advances, 2020, 4, 1350-1356.	5.2	19
105	Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. Cell Reports Methods, 2022, 2, 100236.	2.9	19
106	Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia, 2015, 29, 788-797.	7.2	18
107	In Vivo 19F-Magnetic Resonance Imaging of Adoptively Transferred NK Cells. Methods in Molecular Biology, 2016, 1441, 317-332.	0.9	18
108	Acquisition, Preparation, and Functional Assessment of Human NK Cells for Adoptive Immunotherapy. Methods in Molecular Biology, 2010, 651, 61-77.	0.9	18

#	Article	IF	Citations
109	Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. Seminars in Hematology, 2020, 57, 201-212.	3.4	17
110	Evaluation of serum-free media formulations in feeder cellâ€“stimulated expansion of natural killer cells. Cytotherapy, 2020, 22, 322-328.	0.7	17
111	TgfÎ²-Imprinting Decrease CD38 Expression and Lead to Metabolic Reprogramming on Primary NK Cell. Blood, 2020, 136, 4-4.	1.4	16
112	Rotavirus Vaccines. New England Journal of Medicine, 2006, 354, 1747-1751.	27.0	15
113	C/EBPÎ² suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genetics and Cytogenetics, 2007, 177, 108-114.	1.0	15
114	Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. European Journal of Cancer, 2010, 46, 2771-2780.	2.8	15
115	Recurrent Stimulation of Natural Killer Cell Clones with K562 Expressing Membrane-Bound Interleukin-21 Affects Their Phenotype, Interferon-Î³ Production, and Lifespan. International Journal of Molecular Sciences, 2019, 20, 443.	4.1	15
116	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE, 2020, 15, e0224775.	2.5	15
117	Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. , 2021, 9, e002267.		14
118	Granulocytic Sarcoma Presenting as Pneumonia in a Child With t(8;21) Acute Myelogenous Leukemia: Diagnosis by Fluorescent In Situ Hybridization. Journal of Pediatric Hematology/Oncology, 2004, 26, 431-434.	0.6	13
119	PET imaging of T cells derived from umbilical cord blood. Leukemia, 2009, 23, 620-622.	7.2	13
120	ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas. Biology of Blood and Marrow Transplantation, 2017, 23, S136-S137.	2.0	13
121	Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Cytotherapy, 2020, 22, 369-376.	0.7	13
122	CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity. Blood, 2020, 136, 3-3.	1.4	13
123	Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood, 2008, 112, 154-154.	1.4	13
124	Regulatory Considerations for NK Cells Used in Human Immunotherapy Applications. Methods in Molecular Biology, 2016, 1441, 347-361.	0.9	12
125	Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients. Bone Marrow Transplantation, 2016, 51, 27-33.	2.4	12
126	Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. Blood Advances, 2018, 2, 1818-1827.	5.2	11

#	Article	IF	Citations
127	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Pediatric Blood and Cancer, 2018, 65, e27313.	1.5	11
128	Expression of carcinoma, apoptosis, and cellâ€deathâ€“related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatric Blood and Cancer, 2019, 66, e27783.	1.5	11
129	Novel cytokineâ€“antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma. , 2020, 8, e001238.		11
130	Natural Killer Cell Immunotherapy for Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1257, 141-154.	1.6	11
131	Cerebral organoids containing an AUTS2 missense variant model microcephaly. Brain, 2023, 146, 387-404.	7.6	11
132	Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function. Blood Advances, 2021, 5, 4605-4618.	5.2	10
133	Disruption of SOCS3 Promotes the Anti-Cancer Efficacy of Primary NK Cells. Blood, 2018, 132, 5687-5687.	1.4	10
134	Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplantation, 2014, 49, 1109-1112.	2.4	9
135	Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biology of Blood and Marrow Transplantation, 2018, 24, 337-342.	2.0	8
136	Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Frontiers in Veterinary Science, 2021, 8, 672361.	2.2	8
137	Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 8006-8006.	1.6	8
138	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. Frontiers in Oncology, 2022, 12, 834002.	2.8	8
139	Electroporation of siRNA to Silence Gene Expression in Primary NK Cells. Methods in Molecular Biology, 2016, 1441, 267-276.	0.9	7
140	Activated peripheral T lymphocytes undergo apoptosis when cultured with monocytes activated by HLA class II ligation. Cellular Immunology, 2003, 225, 101-112.	3.0	6
141	Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia, 2010, 24, 1059-1062.	7.2	6
142	CD38 Knockout Primary NK Cells to Prevent "Fratricide" and Boost Daratumumab Activity. Blood, 2019, 134, 870-870.	1.4	6
143	Combination of Gene Therapy and Nanoparticle Imaging for Improving T-Cell Therapy.. Blood, 2010, 116, 1479-1479.	1.4	6
144	Evaluation of allogeneic and autologous membrane-bound IL-21â€“expanded NK cells for chronic lymphocytic leukemia therapy. Blood Advances, 2022, 6, 5641-5654.	5.2	6

#	Article	IF	Citations
145	Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatric Blood and Cancer, 2010, 55, 1180-1184.	1.5	5
146	The off-target effects of nonspecific NK cells. Blood, 2015, 125, 744-745.	1.4	5
147	Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. Journal of Allergy and Clinical Immunology, 2019, 144, 594-597.e4.	2.9	5
148	Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood, 2013, 122, 2167-2167.	1.4	5
149	The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Current Treatment Options in Oncology, 2022, 23, 381-403.	3.0	5
150	Generation of Natural Killer Cell Lymphoma Models In Vitro by Gene Editing. Blood, 2016, 128, 2724-2724.	1.4	4
151	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget, 2020, 11, 3035-3047.	1.8	4
152	EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatric Blood and Cancer, 2008, 50, 728-730.	1.5	3
153	Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation, 2021, 25, e14041.	1.0	3
154	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. Blood, 2019, 134, 700-700.	1.4	3
155	Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Blood, 2016, 128, 500-500.	1.4	3
156	Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.. Journal of Clinical Oncology, 2018, 36, 7008-7008.	1.6	3
157	CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers. Blood, 2019, 134, 3597-3597.	1.4	3
158	Engineering Receptor Expression on Natural Killer Cells Through Trogocytosis. Methods in Molecular Biology, 2016, 1441, 253-265.	0.9	2
159	IMMU-19. LSD1 MODULATES NK CELL IMMUNOTHERAPY THROUGH AN ONCO-IMMUNOGENIC GENE SIGNATURE IN DIPG. Neuro-Oncology, 2018, 20, i102-i102.	1.2	2
160	Protect NIH's DNA advisory committee. Science, 2018, 362, 409-410.	12.6	2
161	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplantation and Cellular Therapy, 2021, 27, 926.e1-926.e10.	1.2	2
162	Assessment of antitumor function of NK cells expanded with exosomes from K562.mb21 cells.. Journal of Clinical Oncology, 2017, 35, 132-132.	1.6	2

#	Article	IF	Citations
163	A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2020, 136, 44-44.	1.4	2
164	Non-invasive fluorescence imaging for tracking immune cells in preclinical models of immunotherapy. Methods in Cell Biology, 2022, 167, 163-170.	1.1	2
165	IMMU-22. NATURAL KILLER CELL IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i103-i103.	1.2	1
166	Donor Lymphocyte Infusions versus Cytokine-Induced Killer Cells for Hematologic Malignancies after Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e219-e220.	2.0	1
167	Donor-Derived Cytokine-Induced Killer Cells after Nonmyeloablative Transplant for Myeloid Neoplasms. Biology of Blood and Marrow Transplantation, 2019, 25, e221-e222.	2.0	1
168	Combining ROR1- Specific Chimeric Antigen Receptor (CAR) NK Cells with IL-15 Superagonist (N-803/ALT-803) to Target Chemotherapy Resistant Neuroblastoma. Biology of Blood and Marrow Transplantation, 2019, 25, S334.	2.0	1
169	Optimization and Validation of CAR Transduction into Human Primary NK Cells Using CRISPR and AAV. SSRN Electronic Journal, 0, , .	0.4	1
170	Preclinical assessment of PM21-particle expanded natural killer cells for ovarian cancer treatment.. Journal of Clinical Oncology, 2017, 35, 127-127.	1.6	1
171	NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells. Blood, 2019, 134, 2667-2667.	1.4	1
172	IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL. Blood, 2019, 134, 4302-4302.	1.4	1
173	Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 11-12.	1.4	1
174	Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449). Blood, 2020, 136, 2-4.	1.4	1
175	Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). Blood, 2020, 136, 23-24.	1.4	1
176	Long-term Use of Hydroxyurea for Sickle Cell AnemiaLong-term Use of Hydroxyurea for Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 290, 752.	7.4	0
177	Large scale generation of genetically modified T-cells using micro-electroporators for cancer treatments. , 2009, , .		0
178	Trace Evidence: Identifying Natural Cancer Killers After the Crime. EBioMedicine, 2015, 2, 1276-1277.	6.1	0
179	Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. Blood, 2005, 106, 2052-2052.	1.4	0
180	Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. Blood, 2005, 106, 2746-2746.	1.4	0

#	Article	IF	Citations
181	Human Bone Marrow Mesenchymal Stem Cells Enhance Extramedullary Engraftment and Proliferation of Human AML Blasts in NOD-SCID Mice.. Blood, 2005, 106, 2312-2312.	1.4	0
182	Leukemia Targeting Via Cytotoxic T Cells Expressing a CD33 Specific Chimeric Receptor.. Blood, 2006, 108, 453-453.	1.4	0
183	Differential Expression of VEGF Receptors on Human T Cell Subsets. Blood, 2008, 112, 4906-4906.	1.4	0
184	The Contribution of Signaling Endodomains to CD33-Mediated Killing of Acute Myeloid Leukemia by Natural Killer Cells Transiently Modified with Chimeric Antigen Receptor.. Blood, 2009, 114, 2463-2463.	1.4	0
185	Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching. Blood, 2018, 132, 4647-4647.	1.4	0
186	Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies. Blood, 2018, 132, 732-732.	1.4	0
187	Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL). Blood, 2018, 132, 3697-3697.	1.4	0
188	Improved Bone Marrow Homing of NK Cells through PM21 Particle Stimulated Enhancement of Fucosylation of E-Selectin Ligand. Blood, 2019, 134, 3598-3598.	1.4	0
189	A Multi-Omics Approach for Evaluating the Impact of Cytokines and Donor Source on NK Cell Expansion. Blood, 2021, 138, 1769-1769.	1.4	0
190	Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching. Blood, 2020, 136, 42-43.	1.4	0
191	Assessment of Beta-2 Microglobulin Gene Edited Airway Epithelial Stem Cells as a treatment for Sulfur Mustard Inhalation. Frontiers in Genome Editing, 2022, 4, 781531.	5.2	0
192	Role of NK-Like CD8 ⁺ T Cells during Asymptomatic Borrelia burgdorferi Infection. Infection and Immunity, 2022, , e0055521.	2.2	0